COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,796 Articles (22,527 medRxiv, 8,269 bioRxiv)

Most recent first Previous |  Page 1059: Articles 10581-10590  | Next

Myeloid cell-driven nonregenerative pulmonary scarring is conserved in multiple nonhuman primate species regardless of SARS-CoV-2 infection modality
Fears, A. C., Beddingfield, B. J., Chirichella, N. R., Slisarenko, N., Killeen, S. Z., Redmann, R. K., Goff, K., Spencer, S., Picou, B., Golden, N., Bush, D. J., Branco, L. M., Boisen, M. L., Gao, H., Montefiori, D., Blair, R. V., Doyle-Meyers, L. A., Russel-Lodrigue, K. E., Maness, N. J., Roy, C. J.
10.1101/2021.11.28.470250 — Posted: 2021-11-30
A recombinant SARS-CoV-2 RBD antigen expressed in insect cells elicits immunogenicity and confirms safety in animal models
Choque-Guevara, R., Poma-Acevedo, A., Montesinos-Millan, R., Rios-Matos, D., Gutierrez-Manchay, K., Montalvan, A., Quinones-Garcia, S., Cauti-Mendoza, M. d. G., Agurto-Arteaga, A., Ramirez-Ortiz, I., Criollo-Orozco, M., Huaccachi-Gonzales, E., Lazaro, Y. K. R., Perez-Martinez, N., Isasi-Rivas, G., Sernaque-Aguilar, Y., Villanueva-Perez, D., Vallejos-Sanchez, K., Fernandez-Sanchez, M., Guevara, L., Fernandez-Diaz, M., Zimic, M., COVID-19 Working Group in Peru
10.1101/2021.11.26.470043 — Posted: 2021-11-30
COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis
Sinha, S., Castillo, V., Espinoza, C. R., Tindle, C., Fonseca, A. G., Dan, J. M., Katkar, G. D., Das, S., Sahoo, D., Ghosh, P.
10.1101/2021.11.28.470269 — Posted: 2021-11-30
On the Role of Financial Support Programs in Mitigating the Sars-CoV-2 Spread in Brazil
Albani, V. V. L., Albani, R. A. S., Bobko, N., Massad, E., Zubelli, J. P.
10.1101/2021.11.30.21267063 — Posted: 2021-11-30
Risk of Hospitalization, severe disease, and mortality due to COVID-19 and PIMS-TS in children with SARS-CoV-2 infection in Germany
Sorg, A.-L., Hufnagel, M., Doenhardt, M., Diffloth, N., Schroten, H., von Kries, R., Berner, R., Armann, J. P.
10.1101/2021.11.30.21267048 — Posted: 2021-11-30 Discussion: Onsite
Identification of susceptibility loci for adverse events following COVID-19 vaccination in the Japanese population: A web-based genome-wide association study.
Nogawa, S., Kanamori, H., Tokuda, K., Kawafune, K., Chijiiwa, M., Saito, K., Takahashi, S.
10.1101/2021.11.30.21267043 — Posted: 2021-11-30
The immunogenicity and safety of different COVID-19 booster vaccination following CoronaVac or ChAdOx1 nCoV-19 primary series
Angkasekwinai, N., Niyomnaitham, S., Sewatanon, J., Phumiamorn, S., Sukapirom, K., Senawong, S., Mahasirimongkol, S., Toh, Z. Q., Umrod, P., Somporn, T., Chumpol, S., Ritthitham, K., Chokephaibulkit, K.
10.1101/2021.11.29.21266947 — Posted: 2021-11-30
Favipiravir for the Treatment of Coronavirus Disease 2019; a propensity score-matched cohort study
ALATTAR, R. A., ABDALLA, S., ABDALLAH, T. A., KAZMAN, R., QADMOUR, A., IBRAHIM, T. B., ALHARIRI, B., SHAAR, S., BAJWA, A., ALIMAM, A. B., QAZI, R., BEN ABID, F., DAGHFAL, J., ELDEEB, A. M., SHUKRI, K., ELSAYED, A., RUSTOM, F., ALSAMAWI, M., ABDELMAJID, A., BASULTO, M. A., COBIAN, A. A., ABUKHATTAB, M., ALMASLAMANI, M. A., ALKHAL, A., OMRANI, A. S.
10.1101/2021.11.29.21267042 — Posted: 2021-11-30
COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme
Fasching, C. L., Servellita, V., McKay, B., Nagesh, V., Broughton, J. P., Brazer, N., Wang, B., Sotomayor-Gonzalez, A., Reyes, K., Streithorst, J., Deraney, R. N., Stanfield, E., Hendriks, C. G., Miller, S., Ching, J., Chen, J. S., Chiu, C. Y.
10.1101/2021.11.29.21267041 — Posted: 2021-11-30 Discussion: Onsite
Population level impact of a pulse oximetry remote monitoring programme on mortality and healthcare utilisation in the people with covid-19 in England: a national analysis using a stepped wedge design
Beaney, T., Clarke, J., Alboksmaty, A., Flott, K., Fowler, A., Benger, J. R., Aylin, P., Elkin, S., Neves, A. L., Darzi, A.
10.1101/2021.11.29.21266847 — Posted: 2021-11-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).